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Abstract
Drug resistance is a major obstacle for controlling infectious diseases. A key challenge is detecting
the early signs of drug resistance when little is known about its genetic basis. Focusing on malaria
parasites, we propose a way to do this. Newly developing or low level resistance at low frequency
in patients can be detected through a phenotypic signature: individual parasite variants clearing
more slowly following drug treatment. Harnessing the abundance and resolution of deep
sequencing data, our ‘selection differential’ approach addresses some limitations of extant
methods of resistance detection, should allow for the earliest detection of resistance in malaria or
other multi-clone infections, and has the power to uncover the true scale of the drug resistance
problem.
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Drug resistance and clearance curves
The evolution of drug resistant pathogens is a major challenge in the fight to control
infectious diseases. Malaria parasites are a prime example of this: resistance has evolved to
nearly every anti-malarial drug in use [1] and appears to be emerging against the current
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front-line artemisinin derivatives [2–7]. Ensuring the continued efficacy of these important
drugs requires good surveillance, early and rapid detection of resistance, and containment of
its spread [3,8–13]. Ideally, resistance would be detected when it is at a low level (drug
‘tolerance’) and low frequency in a patient, well before it has become a clinical problem.
Once a new drug resistance mutation has generated sufficient treatment failure to arouse
suspicion, its spread is probably well advanced. Current methods used to detect resistance
struggle to detect rare or low level resistance. Here we propose a new approach that in
principle has substantially greater sensitivity.
Three main tools are used to detect drug resistant malaria parasites. For simplicity, we here
use the term ‘resistance’ to include any significant reductions in drug sensitivity below that
found in wild type populations prior to drug use, including weak resistance or drug
tolerance, though we note that there is disagreement over whether these phenotypes should
be considered resistance [14,15]. These three tools are: (i) molecular markers of resistance,
(ii) in vitro susceptibility tests, and (iii) therapeutic efficacy tests. Limitations of these
approaches have been described in detail elsewhere (e.g., [12,16,17]). Briefly, searching for
molecular markers requires knowledge of parasite candidate genes or pathways, yet little can
be known in advance about the mechanisms underlying resistance when it is just starting to
emerge. This is particularly so in malaria parasites where resistance mechanisms frequently
involve loci other than those encoding drug targets [18]. Further, the list of known genetic
markers of resistance will never be an exhaustive set of all pathways to resistance; new
resistance mechanisms could regularly be evolving, and mechanisms need not be genetic.
Testing the susceptibility of parasites to drugs in vitro is problematic because in vivo
phenotypes do not necessarily correlate with in vitro performance (e.g., [4]), in addition to
being technically challenging, laborious, and expensive. While less technically demanding,
therapeutic efficacy tests are logistically challenging and imprecise. The World Health
Organization protocol [19] involves extensive follow up, monitoring patients for up to one
month or more, during which time any estimate of resistance could be confounded by
reinfections or relapses from liver stages. That protocol also sets out rigid criteria for
parasitemia and other symptoms over the course of infections that indicate parasite
resistance, thus failing to control for any possible sources of inter-individual variation (e.g.,
host factors such as immunity, drug compliance, or coinfection) [8,11,16,20,21].
Recent studies of drug resistance in malaria parasites have addressed some of these
problems by using a more quantitative tool for assaying therapeutic efficacy, the parasite
clearance curve [2,4,6,7,22,23]. The remarkable efficiency with which artemisinins act
generates a pattern of log-linear decline in parasite densities on a very short timescale [24–
26]. With sufficiently frequent sampling of parasite densities, the slope of their decline can
be used to calculate a half-life (the time it takes for parasites to reach half of their initial
density) [24,27,28]. Parasites that are cleared more slowly from a patient have longer half-
lives and are deemed more ‘resistant’. Comparisons of the average half-lives of parasites in
different host populations have demonstrated artemisinin resistance emerging in Cambodia
[4,5,6], Thailand [2], and Myanmar [7] and failing to emerge, for now, in Laos [23] and
Mali [29].
Parasite clearance curves are important tools for defining host population level distributions
of parasite half-lives, and they have the advantage of being able to account for some of the
variation that occurs between hosts. For instance, some infections show a lag phase before
parasite densities start to drop after treatment is initiated, or a tail phase where parasite
densities remain above the detectable threshold after a period of log-linear decline [24,27].
The Parasite Clearance Estimator [27] controls for these non-linearities when estimating a
half-life. While these patterns could be the result of host effects, they could also be
measurement errors or, importantly, could indicate parasite subpopulations within a host that
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respond differently to treatment [24]. Parasite clearance curves are not able to give finer
resolution on this sort of within-host variation since they are not designed for making
patient-level inferences. A parasite clearance curve offers a single estimate of the clearance
rate of parasites: a weighted average of the clearance trajectories of all parasites within a
patient [24]. Malaria infections in humans seldom consist of one parasite clone; many
parasite genotypes share their hosts with other genotypes (e.g., [30–38]). A consequence of
this is that resistant parasites will often share their host with sensitive parasites, particularly
early in the evolutionary process as resistance is spreading. The interpretation of clearance
curves for individual patients is affected by this within-host diversity.
Consider a patient that harbors two parasite clones: a fast-clearing, drug-sensitive clone and
a slow-clearing, drug-resistant clone. When the individual clearance curves of these two
different clones cannot actually be distinguished, two opposing conclusions can be reached,
depending on the relative frequency of the clones. If these two clones are at equal
frequencies in a patient when drug treatment is initiated, then the clearance curve observed
follows the trajectory of the resistant parasite, since it quickly becomes numerically
dominant in a drug-treated infection (Figure 1A). If, however, the resistant clone is initially
at low frequency in the patient, then our ability to ‘see’ those resistant parasites in the
infection is vastly diminished. The clearance curve now follows the trajectory of the
sensitive clone (Figure 1B). From clearance curves alone, it is impossible to tell that the
patient in Figure 1B is harboring resistant parasites and potentially transmitting those
parasites. Current approaches may therefore underestimate the scale of the drug resistance
problem.
Capitalizing on within-host diversity with next generation approaches
We propose that, rather than being an obstacle to identifying drug resistance in individual
patients, the within-host diversity of infections can instead be exploited to detect it. When
drug treatment is applied to mixed infections, clones with any degree of resistance will rise
in frequency in the parasite population within that host. Even weakly drug tolerant clones
will become more frequent because fully susceptible parasites will be cleared at faster rates.
Thus, an increase in the frequency of any clone-specific genetic marker is indicative of up-
selection by drugs of a tolerant or resistant clone in a sea of susceptible parasites. The
critical requirement for identifying such a change in frequency is a detection technique that
can quantify the relative abundance of different clones and sufficiently sensitive to detect
rare variants in a mixed population. Next generation sequencing (NGS) technologies, when
they are used to deeply sequence a single highly polymorphic region hundreds or thousands
of times in a single infection, can do this. The incredible scale and high resolution of the
data generated through these technologies have exposed the true (and vastly underestimated)
within-host diversity of malaria infections [30,39–42] and prevalence of rare drug-resistant
variants in HIV infections (e.g., [43–46]). Using these same deep sequencing tools to detect
drug resistance in malaria infections, as well as quantify the extent and magnitude of that
resistance, is the logical next step.
With longitudinal samples, including a pre-treatment sample and perhaps as few as one
subsequent sample at least one replicative cycle later, deep sequencing can generate a
picture of how individual parasite variants respond to drug treatment. This approach, which
we refer to as the selection’ differential’ approach because that is what is being estimated
[47], provides access to those clone-specific parasite clearance curves that are unobtainable
with current tools. Revisiting the hypothetical patients described in Figure 1, if deep
sequencing was used to quantify the relative abundance of different clones in place of
tracking parasite densities, a clear signature of drug resistance would emerge regardless of
whether the resistant variant was initially at a high or low frequency (Figure 2). Importantly,
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identifying drug resistance with deep sequencing does not require knowing (or sequencing)
the molecular markers of resistance. Instead, the phenotype of resistance can be seen –
slower clearance, increasing relative abundance – by sequencing any coding region that is
highly polymorphic. Since parasite recombination does not occur within human hosts, such
a gene region is in essence a clone-specific marker. The ability to detect all of the variants in
an infection, and hence the power of the method, will depend on the polymorphism of the
gene region targeted; a high degree of polymorphisms allows for a relatively rare resistant
clone to be exclusively represented by one or a few alleles within an individual infection.
The selection differential approach offers a number of advantages as a tool to detect drug
resistance. First, what we propose is a short-term test (perhaps just two or three replicative
cycles) meaning that even if a parasite variant is below the limit of detection in a pre-
treatment sample (e.g., if sequencing is not sensitive enough to detect a variant at 0.05%, as
depicted in the left panel of Figure 2B), it would be highly unlikely that its detection in a
subsequent sample would be due to a reinfection or relapse. Second, what we propose
should in principal be feasible with as few as two blood samples from patients, although
certainly more power will be garnered by additional time-points, and these may be necessary
if lag phases are a parasite genetic effect (Box 1). Finally, what we propose is intra-patient;
while recent studies have reported that a substantial amount of the variation in clearance
times is attributable to parasite genetics [2,48], some of it is not. With the selection
differential approach, all patient-specific variables (like immune status, coinfection, drug
uptake, compliance, dosing, drug quality, etc.) are held constant while the clearance rates of
individual parasite clones within that patient are investigated.
Box 1
Outstanding questions
• How well do different sequencing platforms estimate the relative abundances of
known mixtures? Given this noise, how rare could a resistant clone be in an
infection and still be detected using the selection differential approach?
• What magnitude of change in relative abundances can be generated through
immune selection alone, i.e., how effective at killing parasites are clone-specific
immune responses? On what timescale are these changes observable?
• How does sampling and sequencing parasites at different stages in their
replicative cycle affect estimates of relative abundance?
• How much variation in cell cycle duration is there among the parasites within an
infection?
• If there is variation in cell cycle duration, and the stage of sampled parasites
affects estimates, what sampling regime could provide a meaningful picture of
the relative abundance of clones?
• Does residual DNA from dying or dead parasites contribute to estimates of
relative abundance from deep sequencing?
• Are the lag phases in parasite clearance curve a host effect (e.g., drug
metabolism) or a parasite effect (e.g., parasite subpopulations that are
inaccessible to drugs) [24]? If lags are parasite effects that are unrelated to drug
sensitivity, how many more samples would be needed to rule out changes in
relative abundance due to different lengths of lag phases?
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Using deep sequencing for early detection of drug resistance is not without its own
challenges (Box 2). Chief among these is discriminating real changes in the relative
abundance of different parasite variants over time from noise. Accurate characterization of
variants within an infection and quantification of the relative abundance of those variants are
key for inferring drug resistance from the changes that occur over the course of treatment.
But deep sequencing is error-prone and observation error will always muddle attempts to
characterize a large parasite population based on a small sample. In a forthcoming article,
we develop statistical methods to analyze the type and quality of data involved and use these
to provide estimates of the power of the approach to detect low frequency and low level
resistance. In Box 3 we illustrate the variation that can arise across technical replicates from
these sources of error and briefly describe how, by borrowing tools from community
ecology, this noise can in principle be harnessed to develop a null expectation and define
thresholds for inferring resistance.
Box 2
Technological challenges
Next generation sequencing of malaria parasites has been used to quantify and track the
clonal diversity within individual infections [30,41,42], to examine diversity and
population genetic patterns at the whole parasite population level (among hosts in a given
region; 39–41], and to correlate population genetic patterns with resistance phenotypes
[58]. These studies represent a combination of whole genome and amplicon sequencing
approaches, and each has its own challenges. For studies using whole genome sequencing
[41,42, 58], relatively large amounts of DNA are required. This necessitates collection of
large volumes of whole blood, cold storage of samples between the field and the lab,
filtering of samples to remove host white blood cells, and, sometimes, short-term in vitro
culturing to increase parasite numbers (and DNA) [59,60]. The key challenges for whole
genome sequencing studies, then, occur at the sampling and sample-processing end of the
pipeline. In addition, when used for studying multi-clone infections, whole genome
sequencing provides limited depth and short reads, both of which limit the ability to
study variants occurring at low frequencies.
These challenges are less of a problem for amplicon sequencing, the approach that we are
advocating. Less DNA is required for amplicon sequencing [30,39,40], and sufficient
volumes can be obtained directly from blood spots on filter paper, which require
desiccation rather than refrigeration for storage. Because amplification of a target locus
by PCR is performed, large blood samples and filtering of host white blood cells are
unnecessary [61]. However, this PCR step also has the potential to introduce base pair
substitutions due to polymerase errors and, more challenging, chimeric sequences due to
incomplete primer extension on one haplotype followed by completion of extension on
another (PCR-mediated recombination; e.g., [62]). Such chimeras are likely a significant
contributor to the noise described in Box 3. These issues shift the key challenges with
amplicon sequencing towards the bioinformatics and sequence-processing end of the
pipeline. Computational tools have been developed to deal with chimeras and other PCR-
introduced artifacts (e.g., [63–65]), but these have so far been restricted to making
assignments in clonal populations or at higher taxonomic levels (i.e., genus-level). For
sexually recombining organisms such as malaria, chimeras, and true recombinants lack a
priori distinguishing features. For now, studies try to circumvent these problems by using
stringent criteria for calling variants, for example by requiring a variant to occur in
multiple technical replicates, as in [39].
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Quantifying resistance through noise
In a recent study [39], DNA was extracted from single blood spots from 100 individual
malaria patients prior to receiving treatment, and then divided into two for PCR and
sequencing. An approximately 250 bp region of the highly polymorphic P. falciparum
csp gene was amplified, and the amplicon product was sequenced on the Roche 454
platform. For each replicate sample from individual patients, reads were clustered into
parasite variants (haplotypes). Based on control sequencing, the authors required that a
variant be at a frequency of at least 1% and occur in both replicates before being
considered a true variant for their analysis. Here we include all initially called variants in
each replicate regardless of their frequency or reproducibility to provide a maximal
estimate of noise. Figure Ia shows the relative abundance of variants, as estimated in the
two technical replicates, for two patients (labeled 1111 and 1128) before treatment. Most
of the 100 patients generate graphs that look like patient 1111, i.e., the frequency of
variants is relatively reproducible across replicates. For a minority of patients (fewer than
10), the pattern looks more like patient 1128, with large shifts in frequency across
replicates. No systematic underlying cause of these shifts could be determined and all
samples passed sequencing quality control cutoffs [39]. The dark blue variant in patient
1128 undergoes precisely the sort of change expected for a drug resistant parasite during
treatment. If such patterns can arise due to noise across a single time point, how can one
be sure that the same pattern across time points indicates resistance?
With such technical replicates from pre-treatment sampling, one can generate a null
expectation against which to compare changes that occur over the course of treatment.
Useful metrics can be adapted from community ecology where measures of dissimilarity
are used to compare species assemblages (e.g., the Bray-Curtis and Manhattan measures;
see [66–69] for overviews). For instance, for each variant within a patient, the distance of
the point given by the two pre-treatment frequency estimates of that variant to the
expected 1:1 line can be calculated. We define d0 as the sum of the distances of all
variants within a patient:
for a patient harboring n variants, where the pre-treatment frequency of the ith variant is
estimated as p0,i (the superscript denotes the technical replicate). In Figure Ib we
illustrate this approach for the two representative patients. Calculating d0 for each of the
100 patients in [39] gives rise to the distribution of d0 values in Figure Ic; this represents
our null expectation against which we could compare the distance of the points in a pre-
versus post-treatment frequency plot to the 1:1 line. If drug treatment changes the relative
abundance of parasite variants due to the presence of resistant variants, then the points in
this plot will lie farther from the 1:1 line. Specifically, if
where pT,i is the post-treatment frequency estimate of the ith variant, then we expect dT to
lie outside of the distribution of d0.
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Implicit in our selection differential approach is an assumption that infections are likely to
be composed of a small number of drug-resistant parasites in a sea of sensitive ones. This
may not be the case in regions of Southeast Asia where resistance to artemisinins is
emerging and where the data suggest that the majority of infections harbor a single clone
(e.g., [2]). In those cases, our approach is irrelevant because parasite clearance curves do an
adequate job (recall Figure 1A). However, if and when resistance spreads to high
transmission settings in Africa (where vigilance and early detection are especially important
[49]), resistant parasites are likely to occur in mixed infections. Indeed, a number of studies
looking for known resistance mutations (i.e., resistance to non-artemisinin drugs) have
found parasites harboring those mutations commonly occurring in mixed infections with
wild-type parasites (e.g., [34,50–52]). Recent work, however, shows that mixed genotype
Plasmodium falciparum infections tend to be composed of closely related parasites [53], and
this could mean that resistant parasites often share an infection with other resistant parasites.
If so, similarly resistant parasite variants in an infection would be cleared at the same rate,
so the relative abundance of those variants would not change. Our proposed approach would
fail to identify infections with resistance at high frequency, but this is not what our approach
aims to do – again, clearance curves do an adequate job in this case. And, because all de
novo mutations for resistance necessarily begin in a mixed infection, if de novo resistance is
a significant source of treatment failure then our approach provides a method to detect these
resistant variants as soon as they appear.
Our approach assumes that parasites in drug-treated infections follow the log-linear
clearance curves discussed earlier, but a number of biological processes could qualitatively
alter these patterns of decline. For instance, what if there are multiple parasite cohorts with
48-hour cycles that are offset by a day? What happens if parasite variants within an infection
vary in their cell cycle duration? In the first case, daily sampling to capture each cohort over
a full replicative cycle should solve the multiple cohort problem. In the second case, it is not
yet clear how variation in cell cycle duration would affect estimates of the relative
abundance of variants over the course of drug treatment. Assuming it affects drug-sensitive
and drug-resistant parasites equally, then this complexity would be captured in any null
distribution (Box 3). If on the other hand drug resistance is a function of this complexity,
e.g., resistance is mediated by changes to cycle length (as has been suggested, e.g., [54])
then the situation may be more complicated and further mechanistic modeling of within-host
processes could shed light on how this would affect measures of change. Our selection
differential approach could also be constrained if drug treatment results in parasite densities
below the threshold required for sequencing before a post-treatment sample is taken. With a
better understanding of the noise and limits of sequencing data, it will be possible to
quantify the parameter space (level and frequency of resistance) over which our approach is
robust.
Finally, selection pressures beyond those imposed by drug treatment may be acting in
infections. This means that the relative abundance of different parasite clones will change
for reasons other than differential sensitivity to drugs (e.g., differential susceptibility to
antigen-specific immune responses) and may obscure the selective effects of drugs.
Understanding the scale of the changes in response to these other pressures could be
achieved with longitudinal samples of untreated asymptomatic infections or with pre- and
post-treatment samples from patients in areas where resistance is currently thought to be
absent. This additional source of noise could also be built into the null expectation (Box 3).
It is our speculation that selection in response to drugs will overwhelm other evolutionary
forces such as selection via biased parasite killing by the immune system. For instance, in
experimental rodent malaria infections, which are more rapidly contained and cleared than
human infections, all immune responses (specific and non-specific) were recently estimated
to kill 85% of parasites per day at maximum efficiency and less than that throughout much
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of the infection [55]. It is unclear how much of that immune killing is strain-specific, but
even the maximum of 85% equates to a parasite reduction ratio of about 10, two to four
orders of magnitude lower than what has been estimated for the efficacy of artemisinins
[25]. This suggests that drug selection has the potential to overwhelm strain-specific
immune selection, but further data (or mechanistic modeling) is needed to understand the
magnitude of selection differentials that can be generated through immunity alone (Box 1).
Concluding remarks and future perspectives
The introduction of NGS technologies brought with it the promise of allowing researchers to
“follow the evolution of…resistance in real time” [56]. The data generated from these
technologies should allow us to see the up-selection of drug resistant parasites within
individual infections. Indeed, deep sequencing has been used, for example, to follow the
dynamics of known resistance mutations in HIV infections [57]. Yet, as we have argued,
these technologies have a much broader utility, allowing for the dynamics of resistance to be
tracked even when genetic resistance mechanisms have yet to be discovered.
The selection differential approach will in principle permit the most rapid diagnosis of
resistance in malaria infections, with the fewest possible blood samples, and the best
possible accuracy (bypassing issues of reinfection and relapse). Further, by allowing
previously undetectable resistant parasites to be identified, these tools could not only
contribute to surveillance and monitoring programs, they could feed samples and data into
studies seeking to identify genetic markers and pathways of resistance. Alternatively, with
candidate mutations identified, the selection differential approach could be adapted to
determine whether candidate resistance alleles are indeed being up-selected during drug
treatment. Finally, should the costs and the turnaround time of the sequencing technology
continue to decrease, it could in theory be possible to use this approach to identify individual
patients who will not respond to treatment, giving clinicians an opportunity to change
treatment regimens or partner drugs before clinical failure occurs. This would have the
benefit of not only improving patient health, but also removing the drug-specific selection
pressure on those parasites.
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• Malaria infections (and many others) often consist of multiple parasite clones
• Current tools cannot detect drug resistant clones at a low frequency in individual
infections
• Deep sequencing can reveal how individual parasite variants respond to drugs
• These tools could provide rapid and robust diagnostics for drug resistance
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Figure 1. Clearance curves of diverse infections
Predicted clearance curves of sensitive (black) and resistant (red) parasite clones in
hypothetical infections after drug treatment is initiated (ignoring any possible lag or tail
phases [24,27]). The blue line shows the clearance curve that would actually be measured
for an individual patient using standard approaches (i.e., it shows the change in the total
parasite density over time). Initial frequencies of the resistant clone are (A) 50% and (B)
0.5%. Half-lives for sensitive and resistant clones are taken from [2] (3.7 hours and 6.2
hours, respectively). Despite harboring resistant parasites in both cases, the infection in (A)
appears resistant while in (B) appears sensitive.
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Figure 2. Relative abundance measures of diverse infections
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Relative abundance of drug-sensitive (black) and resistant (red) parasites before and after
drug treatment of hypothetical infections in Figure 1. Half-lives are as given in Figure 1, and
initial frequencies of the resistant clone are again (A) 50% and (B) 0.5%. In both cases, the
relative abundance of the red parasite variant dramatically increases after drug treatment,
indicating that it is being cleared more slowly than the black variant and providing a striking
signal of resistance. Deep sequencing can provide this sort of data on the relative abundance
of parasite variants.
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Figure I. Noise and the summed distance metric
(A) Relative abundance of parasite variants, as determined by 454 sequencing of an
approximately 250 bp region of the P. falciparum csp gene, from two representative patients
[39]. For each patient, the relative abundances have been estimated twice (technical
replicates, R1 and R2). Within patients, each colour represents a unique parasite variant. (B)
Plotting these frequencies in a different way reveals a metric for quantifying noise. Here,
each point represents the two estimates of frequency for an individual parasite variant. The
dotted lines indicate the distance to the 1:1 line, and the d0 values are the sums of these
distances for all variants within that patient. If technical replicates were perfectly repeatable,
all points would lie along the 1:1 line and d0 would be 0. (C) The distribution of d0 values
calculated from all 100 patients in [39], as well as a fitted exponential curve (red; λ=11.8).
The dotted lines indicate the values of d0 below which 95, 99 or 99.9% of the fitted
distribution lies (equivalently, dT values above these cutoffs are expected to occur less than
5, 1, or 0.1% of the time by chance alone).
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